Buy Casodex (Bicalutamide) Online — AstraZeneca ORIGINAL Selective Non-Steroidal Antiandrogen for Stage D2 Metastatic Prostate Cancer Combined Blockade

Three ways Casodex is used

Combined androgen blockade (CAB). Casodex 50 mg daily plus an LHRH agonist injection (leuprolide, goserelin, triptorelin) - the classical advanced prostate cancer regimen. Attacks the pathway from two directions.

Flare prevention. Casodex 50 mg daily started 3-7 days before the first LHRH agonist injection - covers the brief testosterone rise that LHRH agonists cause at start of therapy.

Monotherapy at 150 mg in locally advanced disease - keeps testosterone levels normal while blocking the receptor, preserving libido and physical function better than castration.

Three prescribing contexts

Metastatic disease, combined androgen blockade. Casodex 50 mg daily plus a monthly or three-monthly LHRH injection. Continued indefinitely until progression. Modest survival benefit over LHRH alone.

LHRH agonist tumour flare cover. Casodex 50 mg daily started days before the first LHRH injection. Continued for 2-4 weeks after. Prevents the transient testosterone rise from worsening bone pain or triggering spinal cord compression in symptomatic disease.

Locally advanced monotherapy at 150 mg. An alternative to castration when the man wants to preserve testosterone-driven function - sexual, muscular, cognitive - and can accept the higher gynecomastia rate as a trade-off. Licensed in Europe and elsewhere; not licensed at this dose in the USA.

Who typically ends up on Casodex

• Men newly diagnosed with metastatic hormone-sensitive prostate cancer where a CAB approach is chosen (versus intensified therapy with a newer agent)
• Men with locally advanced disease wanting hormonal therapy without full castration
• Men with symptomatic bone metastases starting LHRH therapy - flare cover matters here
• Older or frailer men where the tolerability of Casodex outweighs the modest anti-cancer advantage of newer drugs
• Men who cannot tolerate second-generation antiandrogens due to falls, cognitive change, or seizure risk
• Men in resource-limited settings where newer agents are unaffordable

Where doctors reach for other drugs first

• High-volume metastatic hormone-sensitive disease: enzalutamide, apalutamide, or abiraterone give better survival than classical CAB
• Non-metastatic castration-resistant disease: PROSPER, SPARTAN, ARAMIS establish the newer agents here
• Aggressive disease with visceral metastases: docetaxel plus intensified hormonal therapy
• Prior progression on Casodex-based CAB: move to a next-line agent

Why two drugs instead of one

The LHRH agonist: reduces testosterone production by the testes. After 3-4 weeks serum testosterone drops to castrate level (typically under 50 ng/dL). This eliminates the main source of androgen but does not eliminate all androgen - about 5-10 percent of circulating androgens still come from the adrenal glands, and intracellular DHT conversion continues.

Casodex 50 mg daily: blocks the androgen receptor. Any remaining androgen - adrenal in origin, or intracellular DHT - cannot signal because receptors are occupied. Together the two drugs approach complete androgen blockade.

What the meta-analyses have shown

The Prostate Cancer Trialists' Collaborative Group meta-analysis (Lancet 2000) pooled data from over 8 000 men across 27 trials. Combined androgen blockade with a non-steroidal antiandrogen added approximately 2-3 percent absolute survival benefit at 5 years versus LHRH agonist alone. Modest but real. This is the trial evidence that made CAB standard in many centres for decades.

The modern challenge to classical CAB

Since around 2015, several landmark trials have shown that newer androgen receptor inhibitors combined with an LHRH agonist outperform classical CAB with bicalutamide:

• ENZAMET (NEJM 2019) - enzalutamide + testosterone suppression versus standard antiandrogen (bicalutamide, nilutamide, or flutamide) + testosterone suppression; enzalutamide arm had better overall survival
• TITAN (NEJM 2019) - apalutamide + LHRH; substantial survival advantage
• ARCHES (JCO 2019) - enzalutamide added to standard ADT; better radiographic progression-free survival
• LATITUDE (NEJM 2017) - abiraterone + prednisone + LHRH in high-risk metastatic hormone-sensitive disease; large survival benefit
• STAMPEDE abiraterone comparison - similar magnitude survival advantage

So in high-volume newly diagnosed metastatic disease, modern practice often skips bicalutamide and uses enzalutamide, apalutamide, darolutamide, or abiraterone alongside the LHRH agonist.

Where Casodex-based CAB still fits in 2026

• Low-volume metastatic disease where newer agents show more modest benefit
• Older or frailer men who might not tolerate second-generation drugs well
• Men with prior falls, cognitive impairment, or specific comorbidities
• Cost-constrained settings where enzalutamide, apalutamide, or abiraterone are unaffordable
• As flare cover for the first weeks of LHRH therapy only, not indefinite CAB
• Patients already on stable long-term CAB with well-controlled disease - continued rather than switched preemptively

The physiological difference from CAB

On combined androgen blockade with an LHRH agonist, testosterone drops to castrate levels. The patient becomes chemically castrated. The full menopause-equivalent picture develops: hot flushes, loss of libido, erectile dysfunction, muscle mass loss, bone loss, weight gain, cardiovascular changes, mood shifts.

On Casodex 150 mg monotherapy, testosterone stays normal or actually rises modestly (feedback from receptor blockade increases LH output). Libido and sexual function are largely preserved. Bone density is preserved. Muscle mass is preserved. Cardiovascular consequences are much milder. This is one of the significant quality-of-life advantages of the monotherapy approach.

The trade-off - what you accept

• Very high gynecomastia rates - roughly 70 percent of men develop breast enlargement, often bilateral, sometimes with tenderness. This is the biggest downside of monotherapy
• Modestly less anti-cancer effect than combined androgen blockade in aggressive disease
• Some hot flushes (much fewer than on castration - 12-15 percent versus 60-70 percent)
• Small but real liver toxicity risk requiring monitoring

What the evidence supports

The Early Prostate Cancer (EPC) Programme - three linked trials totalling 8 113 men - directly studied Casodex 150 mg in localised and locally advanced prostate cancer. In locally advanced disease (T3-T4 or high-grade tumours), Casodex 150 mg reduced disease progression and improved outcomes versus watchful waiting or standard care. This is the evidence base for the European licensing of monotherapy at 150 mg. Section 8 covers EPC in detail.

Not for localised low-risk disease

EPC data showed that Casodex 150 mg monotherapy in localised low-risk prostate cancer was harmful - no cancer benefit, and increased non-cancer mortality. The regulatory approval for this indication was withdrawn. Casodex monotherapy is not appropriate for early low-risk disease. Active surveillance, prostatectomy, or radiotherapy fit those settings instead.

Regulatory difference across countries

Casodex 150 mg is licensed in Europe, the UK, Canada, Australia, and many other markets for locally advanced prostate cancer monotherapy. It is not licensed at this dose in the USA - only 50 mg is FDA-approved. American oncologists use 50 mg only, in combination with LHRH agonists. This is a real regulatory difference that affects what your treating team can prescribe.

The flare phenomenon

LHRH agonists (leuprolide, goserelin, triptorelin, histrelin) work through a paradox. Initially they overstimulate the pituitary's LH-releasing receptors, producing a surge of LH and a spike in testosterone. Testosterone can rise to 150 percent of baseline in the first 1-2 weeks. After that the pituitary receptors desensitise and testosterone falls to castrate level.

For asymptomatic men the transient spike causes nothing. For symptomatic men it can drive:

• Worsening bone pain from bone metastases
• Rare but serious spinal cord compression
• Urinary retention if there is significant prostatic obstruction
• Occasional cardiovascular events

How Casodex covers the flare

Bicalutamide occupies androgen receptors within days of starting. When the LHRH-induced testosterone surge arrives, receptors are already blocked. The extra testosterone cannot signal to the prostate cancer cells. The flare symptoms are largely prevented.

The standard flare cover regimen

• Start Casodex 50 mg daily 3-7 days before the first LHRH injection
• Continue for 2-4 weeks after the first injection
• Stop Casodex once testosterone is confirmed at castrate level, unless the plan is combined androgen blockade long-term
• If CAB is the intended long-term strategy, simply continue Casodex indefinitely at 50 mg

Men who especially need flare cover

• Symptomatic bone metastases - especially in the spine where cord compression could be catastrophic
• Significant urinary obstruction from prostate enlargement
• Very high PSA or heavy metastatic burden - more responsive tissue to protect
• Baseline pain from disease - flare would worsen this
• Any high-risk anatomical situation where sudden tumour flare could damage function

The LHRH antagonist alternative

LHRH antagonists such as degarelix (injection) and relugolix (oral) do not cause flare because they block the pituitary receptor directly rather than initially overstimulating it. Testosterone drops within a few days without any preceding rise. Men who need immediate testosterone suppression without any risk of flare are often started on an LHRH antagonist instead of an LHRH agonist plus Casodex flare cover. Both strategies work; the choice depends on cost, availability, and local practice patterns.

The androgen pathway in prostate cells

Circulating testosterone enters prostate cells through diffusion. Inside the cell, the enzyme 5-alpha reductase converts most of it into dihydrotestosterone (DHT) - a more potent androgen. Both testosterone and DHT bind the androgen receptor (AR), an intracellular receptor that acts as a transcription factor.

Ligand-bound AR undergoes a conformational change, releases from heat shock proteins, dimerises, and moves into the nucleus. There it binds specific DNA sequences called androgen response elements and activates gene transcription. The transcribed genes drive prostate cell survival and growth. In healthy prostate this maintains normal function. In prostate cancer it drives malignant proliferation.

What Casodex specifically does

Bicalutamide is a non-steroidal, competitive, reversible antiandrogen. It enters cells and binds the AR ligand-binding domain, competing with testosterone and DHT. When bicalutamide occupies the receptor:

• Testosterone and DHT cannot bind
• The receptor still moves into the nucleus but cannot activate target genes properly
• Cell proliferation slows or stops
• PSA production drops
• Tumour cell death (apoptosis) is triggered in responsive cells

Why the drug does not lower testosterone

Bicalutamide blocks the receptor. It does not touch the testes or the pituitary. Testosterone production continues at baseline (or actually increases slightly due to feedback effects when the drug is given as monotherapy - reduced androgen signalling makes the pituitary produce more LH, which drives more testicular testosterone). This is why monotherapy at 150 mg preserves masculine physiology in ways that castration cannot.

Pharmacokinetics that shape dosing

• Serum half-life around 6 days - one of the longest half-lives in oncology
• Steady state at 4-6 weeks after starting therapy
• Metabolised primarily by CYP3A4 then glucuronidated
• Excreted equally in urine and faeces as inactive metabolites
• Two enantiomers exist (R and S); the R form is pharmacologically active
• Absorption is unaffected by food; food does not shift efficacy
• Highly protein-bound (about 96 percent) - affects certain drug interactions

Why gynecomastia is such a common side effect

On monotherapy, testosterone stays normal or slightly elevated. Some of that testosterone is converted to estradiol by aromatase in fat tissue and breast tissue itself. Estrogen receptors in breast tissue are stimulated. Meanwhile, androgen receptors in the same breast tissue - which normally push back against estrogen-driven growth - are blocked by bicalutamide. Estrogen effects on breast tissue proceed unopposed. Result: gynecomastia in the majority of monotherapy patients. On CAB with an LHRH agonist, testosterone is low, aromatisation is low, and gynecomastia is much less common (still about 30 percent though).

What Casodex has going for it

• Three decades of clinical safety experience
• Once-daily oral dosing
• Cheap generic bicalutamide available since 2009
• Widely available worldwide including in low-resource settings
• Generally well tolerated at 50 mg
• 150 mg monotherapy option preserves libido and physical function
• Fewer CNS side effects than enzalutamide
• Fewer falls and less fatigue than second-generation agents in older men
• Well-known drug interaction profile

Where the newer drugs beat it

• High-volume metastatic hormone-sensitive disease - enzalutamide (ENZAMET), apalutamide (TITAN), abiraterone (LATITUDE, STAMPEDE) all beat classical CAB
• Non-metastatic castration-resistant disease - PROSPER (enzalutamide), SPARTAN (apalutamide), ARAMIS (darolutamide) established the newer agents
• Post-bicalutamide progression - second-generation drugs still work when Casodex has failed
• Aggressive disease with visceral metastases - maximum receptor blockade matters more than tolerability

The programme structure

• Three parallel trials conducted in North America; Scandinavia and rest of Europe; and Australia, Mexico, and Israel
• 8 113 men in total
• Enrolled men with T1-T4, N0/Nx, M0 prostate cancer - either localised or locally advanced
• Randomised to Casodex 150 mg daily or placebo
• Added to standard local therapy - watchful waiting, radical prostatectomy, or radiotherapy
• Long follow-up with primary publications 2005 and 2008, extended follow-up through 2010

Key findings by clinical setting

Locally advanced disease (T3-T4, higher grade):

• Casodex significantly reduced disease progression
• Overall survival benefit particularly in men on watchful waiting or radiotherapy
• Established the European licensed indication for 150 mg monotherapy
• Sustained benefit at long-term follow-up

Localised disease (T1-T2, low-risk):

• No benefit and possibly worse outcomes
• Increased non-cancer mortality signal
• Regulatory withdrawal of the localised disease indication followed

Adjuvant after radical prostatectomy:

• Reduced biochemical progression
• No clear overall survival benefit at long follow-up
• Substantial side effect burden; discontinuation rates high

Side effect profile from EPC (150 mg dose)

• Gynecomastia: 66-75 percent versus 5-8 percent on placebo
• Breast tenderness: 68-73 percent versus 4-8 percent
• Hot flushes: 12-15 percent (much lower than castration)
• Elevated liver enzymes: 3-4 percent
• Discontinuation for side effects: approximately 20 percent
• Sexual function largely preserved relative to castration
• Bone density largely preserved

Lasting impact on practice

EPC did three important things for how bicalutamide is used today. It established the licensed 150 mg monotherapy indication in locally advanced disease. It removed the drug from the localised low-risk setting where it caused net harm. And it quantified the gynecomastia rate at the higher dose, which led directly to widespread use of prophylactic breast radiotherapy or tamoxifen for men starting monotherapy (Section 29). Twenty years later, EPC still frames how Casodex is prescribed.

The two doses and their uses

Why the doses differ so much

On CAB, testosterone has already been suppressed by the LHRH agonist. There is very little androgen left to compete with bicalutamide at the receptor. 50 mg is sufficient to block the residual signal. Higher doses do not add benefit at castrate testosterone levels - they just add side effects.

On monotherapy, testosterone stays at normal or slightly elevated levels. 50 mg is not enough to compete with these physiological androgen concentrations. 150 mg gives the receptor occupancy needed to control the tumour. This is a real biological dose-response relationship, not a marketing distinction.

Practical dosing rules

• One tablet once daily - either strength
• Same time each day, with or without food
• Do not split or crush tablets
• If the treating team switches you from 50 mg to 150 mg or vice versa, this reflects a change in clinical strategy - ask why
• Duration ranges from weeks (flare cover) to indefinite (CAB or monotherapy)

Doses that are NOT used

• Twice-daily bicalutamide - the 6-day half-life makes this unnecessary
• Higher than 150 mg - no proven additional benefit, more toxicity
• Doses below 50 mg for prostate cancer in adult men
• Casodex in women, children, or premenopausal patients (except off-label transgender care under specialist supervision)

Baseline tests before starting

• PSA - main disease marker for tracking response
• Liver function tests (LFTs) - baseline before ongoing hepatotoxicity monitoring
• Serum testosterone - especially if CAB, to confirm castrate level once LHRH takes effect
• Full blood count and kidney function
• Lipid profile and fasting glucose if long-term therapy expected
• Bone density (DXA) if long-term castration-level testosterone is planned
• ECG in men with prior cardiac history or when QT-affecting drugs are also being started

What most men notice in the first two weeks

• Little or nothing in the first few days
• Some fatigue in the first weeks, more from the LHRH agonist than from Casodex
• Occasional breast fullness or tenderness, especially at 150 mg
• Hot flushes appearing within 2-4 weeks on CAB
• PSA usually falls in the first month if the disease is hormone-sensitive - this is a good sign

Symptoms to report to the team promptly

• Yellowing of eyes or skin - possible liver reaction
• Severe abdominal pain or dark urine
• New or worsening rash - especially with fever or systemic symptoms
• Sudden shortness of breath, chest pain
• Sudden worsening of bone pain - possible inadequate LHRH flare cover
• Any new leg weakness, sensory change, or bladder/bowel dysfunction - urgent, possible spinal cord compression
• Severe unexplained fatigue disproportionate to expectations

The basic dosing rules

• One tablet once daily
• Same time each day, roughly within a few hours
• With or without food; your choice, be consistent
• Swallow whole with water; do not crush or split
• Morning or evening both work equally well

Anchor the dose to a daily habit

• With breakfast - common and easy to remember
• Weekly pillbox refilled every Sunday - the single most effective adherence habit
• Phone reminder labelled "Casodex" or "bicalutamide"
• Keep the pack visible; kitchen counter beats bathroom cabinet
• Refill the prescription 2 weeks before running out
• Travel supply with 30 percent extra

Coordinating with LHRH injections

Men on combined androgen blockade take Casodex daily orally and receive the LHRH agonist as a monthly or three-monthly injection at a clinic. The two do not need to be synchronised - Casodex is on its own daily rhythm; the injection is on a calendar schedule. A missed Casodex dose is a small issue (Section 24); a missed LHRH injection matters more and needs a call to the treating team to reschedule promptly. Book your next injection appointment before leaving the current one - the gaps are firm.

Long-term adherence is the real challenge

Adherence data for prostate cancer hormonal therapy show that around 30-40 percent of men either miss doses regularly or drop out entirely by year 2 of therapy. Side effects fade in urgency, life pressures rise, and it becomes easy to lapse. Missed doses on this scale meaningfully affect outcomes. If side effects or life pressures are making adherence hard, an honest conversation with the treating team almost always beats silent dropout - there are usually options short of stopping entirely.

Direct food effects on Casodex

• Take with or without food - your choice, be consistent
• Large amounts of grapefruit - caution; bicalutamide uses CYP3A4 which grapefruit inhibits
• Seville oranges - similar mechanism to grapefruit
• Occasional grapefruit slice or single juice glass - fine
• St John's Wort - avoid; enzyme induction lowers Casodex levels

Body composition changes on CAB

Men on Casodex plus LHRH agonist commonly gain 3-5 kg in the first year as loss of testosterone shifts body composition. The pattern is characteristic:

• Muscle mass declines (sarcopenia)
• Fat mass increases, especially visceral fat around the waist
• Insulin sensitivity worsens
• Risk of new-onset type 2 diabetes climbs
• Cholesterol drifts up
• Basal metabolic rate falls slightly

On monotherapy at 150 mg, testosterone stays normal and these changes are much smaller. This is one of the practical differences between the two regimens.

A sensible eating pattern

• Mediterranean-style pattern - vegetables, whole grains, oily fish, olive oil, moderate lean meat, legumes
• Protein at 1.0-1.2 g/kg body weight daily - supports muscle preservation, especially important on CAB
• Reduce ultra-processed food - the biggest source of hidden calories, refined carbohydrate, and salt
• Limit simple carbohydrates - insulin sensitivity is already impaired on CAB
• Adequate calcium and vitamin D for bone protection
• Fibre from vegetables, fruit, and whole grains

Exercise plus diet

Diet alone cannot fully counteract the metabolic shift from castration-level testosterone. Resistance training combined with adequate protein is the most effective way to preserve muscle mass and functional status. Weight machines, resistance bands, or bodyweight exercises 2-3 times weekly plus dietary attention beats either intervention alone. Section 27 covers exercise in more detail.

The liver interaction

Bicalutamide causes elevated liver enzymes in 3-5 percent of men, mostly asymptomatic and picked up on routine monitoring. Serious drug-induced liver injury is rare but reported. Heavy alcohol use compounds both the risk and the interpretation - a raised ALT could be the drug, the alcohol, or both, and untangling which is which delays clinical decisions.

Section 19 covers the specific liver monitoring schedule. On Casodex, LFTs are checked at baseline, at 1 and 3 months, then periodically.

Sensible drinking guidance

• Moderate drinking is compatible with Casodex for most men
• Up to 14 units per week, spread out with alcohol-free days (UK CMO guidance)
• Alcohol-free days most of the week
• Avoid binge drinking - especially damaging to liver
• Abstain if LFTs are elevated during any monitoring period
• Cut back during the first months while establishing a stable LFT baseline

Full abstinence indicated when

• Existing chronic liver disease of any cause
• History of alcohol dependence
• LFT rises on routine Casodex monitoring
• Concurrent chemotherapy such as docetaxel or cabazitaxel
• Advanced disease with liver metastases
• Multiple hepatotoxic drugs on board simultaneously

Alcohol and vasomotor symptoms

On combined androgen blockade, alcohol commonly triggers or worsens hot flushes and disrupts sleep. This effect is much less pronounced on monotherapy at 150 mg where testosterone stays normal and vasomotor symptoms are milder anyway. If flushes are troubling you on Casodex-based CAB, reducing alcohol is one of the easier levers to pull first.

Common (over 10 percent of men)

• Gynecomastia (breast enlargement) - 30 percent on 50 mg CAB, 70 percent on 150 mg monotherapy; Section 15
• Breast tenderness - similar rates
• Hot flushes - especially on CAB; Section 16
• Reduced libido on CAB; largely preserved on monotherapy; Section 17
• Erectile dysfunction on CAB
• Fatigue - Section 18

Less common (1-10 percent)

• Elevated liver enzymes - Section 19
• Nausea, GI upset
• Diarrhoea or constipation
• Weight gain - especially on CAB
• Mood changes, depression
• Insomnia
• Rash
• Muscle mass loss on CAB
• Bone density loss on CAB - Section 20

Uncommon

• Anaemia on long-term CAB
• Fluid retention
• Hair thinning
• Dry skin
• Photosensitivity rash
• QT prolongation - Section 22
• Interstitial lung disease - rare

Rare but serious - stop and seek urgent care

• Drug-induced liver injury - yellowing of eyes or skin, dark urine, right upper abdominal pain
• Severe skin reaction - blistering, peeling, mucosal involvement
• Severe interstitial lung disease - progressive breathlessness, dry cough, fever
• Symptomatic QT prolongation - unexplained fainting, palpitations, near-fainting
• Anaphylactic reaction - facial swelling, difficulty breathing
• Severe depression or thoughts of self-harm

Tolerability compared with newer alternatives

Casodex has generally milder tolerability than enzalutamide (fatigue, cognitive effects), apalutamide (rash), or abiraterone (requires prednisone; blood pressure and electrolyte effects). It has more gynecomastia than any of the newer options. This tolerability advantage is one of the reasons Casodex remains widely used despite the newer alternatives - some men simply feel better on bicalutamide than on the next-generation drugs.

Why it happens

Casodex blocks androgen receptors but does not lower testosterone. On monotherapy at 150 mg, testosterone stays normal or slightly elevated. Some of that testosterone is converted by aromatase in fat and breast tissue into estradiol. Estrogen effects on breast tissue proceed unopposed because the androgen counterbalance is blocked. Breast glandular tissue grows.

Rates by dose and regimen

• Casodex 50 mg + LHRH agonist (CAB): gynecomastia in 30-35 percent (testosterone is low, so less aromatisation)
• Casodex 150 mg monotherapy: gynecomastia in 65-75 percent
• Breast tenderness often precedes visible enlargement and occurs in a similar or higher percentage

Typical time course

• Onset within 2-3 months of starting therapy
• Bilateral in most cases
• Firm glandular tissue beneath the nipple - not just fat gain
• Tenderness often precedes visible enlargement
• Can be mildly painful, especially with friction from clothing or contact
• Progresses over 6-12 months then usually stabilises
• Only partial reversal on stopping, especially if well established

Prevention and treatment

Prophylactic breast irradiation: a single low-dose radiotherapy fraction (12-15 Gy) to each breast before starting Casodex monotherapy reduces gynecomastia rates by roughly half. Well-established option; Section 29 covers this.

Tamoxifen 10-20 mg daily: reduces both breast tenderness and enlargement. Best started prophylactically at the same time as Casodex, or as early as possible when symptoms emerge. Small VTE risk to weigh but generally well tolerated.

Anastrozole 1 mg daily: aromatase inhibitor. Less effective than tamoxifen for this specific problem in randomised trials.

Surgery: subcutaneous mastectomy or liposuction for established gynecomastia that persists after stopping Casodex.

When to raise this proactively

For men starting monotherapy at 150 mg, gynecomastia prevention should be part of the initial conversation. Waiting for established gynecomastia and then trying to reverse it is much less effective than preventing it. If your treating team has not raised prophylactic tamoxifen or breast radiotherapy, ask about it. For men on 50 mg CAB, rates are lower and prophylactic measures are less routine, but tamoxifen remains a reasonable option if breast symptoms become bothersome.

Not every breast change is drug-related

A hard, unilateral, non-tender lump - especially in an older man with a cancer history - warrants proper clinical assessment. Male breast cancer is rare but does occur, and Casodex is not the explanation for unilateral masses. Any unusual breast finding should be examined by the treating team rather than assumed to be gynecomastia.

Rates by treatment context

• Casodex + LHRH agonist (CAB): 50-70 percent of men, driven mainly by the LHRH agonist
• Casodex 150 mg monotherapy: 12-15 percent
• Casodex as flare cover: hot flushes appear when the LHRH agonist takes effect after 3-4 weeks
• Severity typically peaks in the first 6 months then eases somewhat over the following year

What they feel like

• A wave of heat starting in the chest or face and spreading upward
• Sweating - anywhere from mild facial flush to drenching night sweats
• Sometimes a racing or fluttering heart
• Duration usually 1-5 minutes per episode
• Night sweats disrupt sleep - often the more troubling form
• Triggers include hot drinks, spicy food, alcohol, and stress

Non-drug management

• Cool bedroom - 17-19 C; fan if a partner prefers warmer
• Cotton or bamboo bed linens and nightwear
• Layered daytime clothing - easy to shed at first sign of a flush
• Avoid triggers - alcohol, spicy meals, hot drinks in the evening, and stress-loaded days
• Regular aerobic exercise - reduces frequency and severity in trials
• Weight management - flushes are worse at higher BMI
• Paced breathing at flush onset - slow deep breaths can shorten episodes

Drug options when non-drug measures are insufficient

• Venlafaxine 37.5-75 mg daily - SNRI with the most trial data for androgen-deprivation flushes
• Gabapentin 300-900 mg at bedtime - particularly effective for night sweats
• Medroxyprogesterone acetate - progestin; effective but has its own side effects
• Cyproterone acetate - steroidal antiandrogen with progestin action; occasionally used specifically for hot flush relief
• Clonidine - older option; less effective than SNRIs
• Acupuncture - some evidence in men with androgen-deprivation flushes; low risk

Not to use for flushes on Casodex

• Testosterone replacement - contraindicated in prostate cancer therapy
• DHEA supplements - can be aromatised to estrogen and worsen gynecomastia
• Untested herbal "male balance" formulations

On monotherapy at 150 mg

• Testosterone stays normal or slightly elevated due to pituitary feedback
• Libido is largely preserved in most men
• Erectile function is largely preserved - some reduction but well short of castration levels
• Ejaculation and orgasm are preserved
• This is one of the strongest arguments for monotherapy when clinically appropriate

On Casodex plus LHRH agonist (CAB)

• Testosterone at castrate level - under 50 ng/dL
• Libido substantially reduced in the majority
• Erectile dysfunction common - 70 percent or more of men
• Reduced ejaculate volume, occasionally anejaculation
• Effects typically appear within the first months and persist through therapy

Managing sexual side effects

• PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) - most useful on monotherapy where libido remains; helpful even on CAB
• Intracavernosal injections (alprostadil) - work even when erectile function is severely impaired
• Vacuum erection devices - non-drug option
• Penile implants - definitive solution for erectile dysfunction when other approaches fail
• Couples counselling and psychosexual therapy - especially for libido and intimacy issues
• Broadening intimacy beyond penetrative sex - realistic and worthwhile conversation for many CAB patients

Raise this proactively

Sexual side effects are one of the most under-reported drug complaints in men. A mix of embarrassment and the assumption that "nothing can be done" keeps this problem in the dark. Both assumptions are wrong. Most urology and oncology teams have established pathways for helping with sexual function during and after prostate cancer therapy. Some centres have dedicated psychosexual clinics linked to the cancer service. Asking is the door that opens the options.

Partner considerations

Sexual side effects affect relationships as much as individuals. Involving a partner in early conversations about what to expect - and in the decision-making about CAB versus monotherapy where both options are clinically viable - avoids surprises and preserves relationships better than adapting silently after the fact.

Where fatigue comes from

• Low testosterone effects on muscle mass and energy metabolism (CAB, not monotherapy)
• Muscle loss reducing baseline metabolic capacity and physical function
• Poor sleep from hot flushes and night sweats
• Anaemia - androgen deprivation drops haemoglobin by around 1 g/dL on average
• Reduced physical activity - deconditioning becomes self-reinforcing
• Cancer-related fatigue - especially in metastatic disease
• Mood effects and depression
• Concurrent chemotherapy where applicable

Interventions that make a real difference

• Regular aerobic and resistance exercise - by far the strongest evidence-based intervention
• Adequate protein and calorie intake - counters muscle loss
• Sleep hygiene and treatment of night sweats
• Address anaemia - iron, B12, folate correction; erythropoietin in specific settings
• Treat depression if present - SNRIs can help both mood and fatigue
• Optimise vitamin D - deficiency worsens fatigue
• Structured cognitive behavioural therapy for cancer-related fatigue - specific programmes exist and work

The exercise paradox

Fatigue makes exercise feel harder to start. But exercise consistently reduces fatigue better than rest does. This is counter-intuitive but well-supported by trial data. Start with what feels sustainable - a 10-15 minute daily walk is a foundation. Add strength training twice weekly after a few weeks. Group exercise programmes for men on prostate cancer therapy (survivorship clinics in some centres) help with both structure and social contact.

Fatigue that needs urgent assessment

• New or rapidly worsening breathlessness
• Fatigue with chest pain or palpitations
• Fatigue with pallor and rapid onset
• Fatigue with new severe bone pain - possible progression
• Fatigue with severe abdominal pain or jaundice

What the drug does to the liver

• 3-5 percent of men develop elevated liver enzymes
• Usually asymptomatic and detected on routine bloods
• Serious drug-induced liver injury is rare (well under 1 percent) but reported
• Occurs at both 50 and 150 mg doses
• Most cases appear in the first 3-6 months of therapy
• Reversible on stopping the drug in almost all cases

Standard monitoring schedule

Symptoms needing urgent liver assessment

• Jaundice - yellowing of eyes or skin
• Dark urine - tea-coloured
• Pale stools - putty-coloured
• Right upper abdominal pain, especially new
• Persistent nausea or loss of appetite
• Unusual bruising or bleeding
• Itching without rash

Any of these need same-day medical review, urgent LFTs, and consideration of stopping Casodex until liver function is clarified.

Interpreting LFT results

• ALT under 3x upper limit of normal: monitor more frequently, usually continue
• ALT 3-5x upper limit: discuss stopping; look for other causes
• ALT over 5x upper limit or bilirubin rising: stop Casodex
• Any clinical hepatitis picture: stop and get specialist assessment

After a liver reaction

Most enzyme elevations resolve within weeks of stopping. Serious hepatitis is followed until full recovery. Rechallenge with bicalutamide after a significant hepatic reaction is not usually attempted - the same drug is likely to produce the same reaction. Enzalutamide or another agent replaces it if hormonal therapy is still needed.

Why CAB damages bone

Testosterone (and estradiol converted from it) supports bone remodelling in men as estrogen does in women. Reducing testosterone to castrate level accelerates bone resorption. Men on long-term androgen deprivation lose bone density at approximately 2-5 percent per year in the hip and spine, particularly in the first years. Fracture risk climbs measurably.

Fracture data

Meta-analyses of men on long-term androgen deprivation show fracture rates approximately double compared with age-matched men not on ADT. Hip fractures particularly matter - one-year mortality after hip fracture in an older man reaches 20-25 percent. Bone protection is not a cosmetic concern.

Bone protection plan on CAB

Every man starting long-term Casodex-based CAB should have:

• Baseline DXA scan
• Vitamin D level - correct deficiency
• Calcium intake at 1 000-1 200 mg daily from food or supplements
• Vitamin D3 supplement 800-1 000 IU daily unless already replete
• Weight-bearing and resistance exercise regularly
• Repeat DXA every 2 years
• Falls risk assessment in older men

When to add a bone-modifying drug

• Baseline T-score below -2.0 on DXA
• T-score falling below -2.0 during therapy
• Any prior fragility fracture
• Rapid bone density loss between DXA scans
• Bone metastases (different indication and dosing regimen)

Options: denosumab (Prolia) 60 mg subcutaneous twice yearly; zoledronate 4-5 mg IV once yearly; oral alendronate or risedronate. In the bone metastases setting, higher-dose denosumab (Xgeva) or zoledronate every 3-4 weeks is used - a different indication with different dosing.

Monotherapy at 150 mg - the different picture

On Casodex monotherapy, testosterone stays normal and bone density is largely preserved. Some evidence even suggests slightly improved bone density from the higher estradiol resulting from unopposed testosterone-to-estrogen conversion. Fracture risk sits close to baseline. Bone monitoring and protective drugs are usually not needed unless there is prior osteoporosis. This is one of the significant quality-of-life advantages of the monotherapy approach.

CAB and cardiovascular risk

Long-term androgen deprivation carries a modest but real cardiovascular signal in observational studies:

• Weight gain and increased visceral fat
• Insulin resistance and higher new-onset type 2 diabetes rates
• Modest lipid changes - LDL rise, triglycerides up
• Small increase in coronary events, mainly in men with pre-existing cardiovascular disease
• Effect appears to accumulate over years of therapy

Monotherapy at 150 mg

Cardiovascular impact is much smaller because testosterone stays normal. The metabolic cluster that drives CAB-related cardiovascular risk is largely absent. Cardiovascular events on 150 mg monotherapy in the EPC trials were similar to placebo, with one exception - a small non-cancer mortality signal in low-risk localised disease that led to withdrawal of that indication.

Standard cardiovascular protection

• Baseline BP, lipids, fasting glucose or HbA1c before starting long-term therapy
• BP at each clinic visit
• Yearly lipids and HbA1c during long-term CAB
• Standard cardiovascular prevention - treat hypertension, statin if indicated, treat diabetes
• Smoking cessation - one of the biggest reversible risks
• Weight management and regular exercise - counters the metabolic drift
• Cardiovascular risk calculator (QRISK, ASCVD, SCORE2) to guide statin decisions

Cardiovascular disease often overtakes cancer

For men diagnosed with prostate cancer in their 60s and 70s, cardiovascular disease is a common eventual cause of death rather than the cancer itself - especially in men with lower-risk disease on long-term hormonal therapy. Managing cardiovascular risk factors during years on Casodex matters as much as taking the drug itself. Do not lose sight of general prevention while focused on the cancer plan.

Cardiovascular symptoms to flag urgently

• Chest pain or discomfort, especially on exertion
• Unusual breathlessness
• New ankle swelling
• Fainting or near-fainting during exertion
• Sustained palpitations
• Sudden severe headache with visual changes

The clinical picture

• Casodex prolongs the QT interval modestly
• Clinically significant arrhythmias are rare on Casodex alone
• Risk rises substantially when combined with other QT-prolonging medications
• Older men and those with structural heart disease are at higher risk
• Low potassium or low magnesium amplifies the risk

When to take extra care

• Baseline ECG recommended in men with cardiac history before starting long-term Casodex
• Baseline electrolytes - correct low potassium or magnesium before starting
• Congenital long QT syndrome - discuss with cardiology before starting
• Prior torsades or unexplained cardiac arrest - Casodex relative contraindication
• Second or third degree heart block, symptomatic bradycardia

Common QT-prolonging drugs to watch for

These add QT effect on top of Casodex - any combination should be checked with the pharmacist:

• Antiarrhythmics - amiodarone, sotalol, dronedarone, procainamide
• Certain antibiotics - macrolides (azithromycin, clarithromycin, erythromycin), fluoroquinolones (moxifloxacin especially), antifungals (fluconazole, ketoconazole)
• Antipsychotics - haloperidol, quetiapine, ziprasidone, thioridazine
• Some antidepressants - citalopram at higher doses, escitalopram, tricyclics
• Ondansetron at higher IV doses
• Methadone
• Hydroxychloroquine and chloroquine

The list is not exhaustive. Any new prescription in a man on Casodex should be checked for QT effect and general interaction potential.

Symptoms of dangerous QT prolongation

• Unexplained fainting - especially with exertion
• Palpitations with dizziness
• Fluttery sensations with near-fainting
• Seizure-like episode - arrhythmia-induced syncope can look like a seizure

Any of these need urgent ECG and cardiology assessment.

Serious - manage carefully

• Warfarin and other coumarin anticoagulants - bicalutamide can potentiate warfarin, prolonging INR; more frequent INR monitoring after starting Casodex or dose changes
• Terfenadine, astemizole, cisapride - largely withdrawn drugs; contraindicated with Casodex (QT plus metabolism concerns)
• Strong CYP3A4 inhibitors - ketoconazole, itraconazole, ritonavir, clarithromycin - raise bicalutamide levels; use with caution
• Strong CYP3A4 inducers - rifampicin, phenytoin, carbamazepine, St John's Wort - lower bicalutamide levels; efficacy may be reduced

Moderate - inform prescriber

• Other QT-prolonging drugs - detailed in Section 22
• Other hepatotoxic drugs - stacked liver load
• Grapefruit and Seville orange in large quantities
• DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) - less studied but interaction unlikely to be clinically important; watch for bleeding
• Antifungals and antivirals that share CYP3A4
• Some antiepileptics - dose adjustments may be needed

Usually safe together

• LHRH agonists (leuprolide, goserelin, triptorelin) - deliberately combined in CAB
• LHRH antagonists (degarelix, relugolix)
• Bone-modifying agents (denosumab, zoledronate)
• Most antihypertensive drugs
• Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin)
• Most SSRIs and SNRIs for hot flushes or depression
• PDE-5 inhibitors (sildenafil, tadalafil) for erectile dysfunction
• Standard vitamins - D3, calcium, B12
• Paracetamol at usual doses - preferred pain reliever

The everyday reminder

Tell every pharmacist and every doctor that you take Casodex. Over-the-counter men's health formulations often contain saw palmetto, DHEA, tribulus, or other components that may interact or work against the drug's intended effect. Standard multivitamins are fine; anything marketed for hormonal or "vitality" effects should be checked with the treating team first.

The rule

• Within 12 hours of usual time: take the missed dose now
• More than 12 hours late: skip it, take the next dose at the usual time
• Never double up
• One missed dose has no clinical consequence
• Two or three missed days - just restart at usual dose

The long half-life buffer

Bicalutamide takes about 6 days to halve in the bloodstream. A single missed dose barely shifts steady-state levels. This is very different from short-half-life drugs where a missed dose leaves you effectively untreated for the day. The pharmacokinetics of Casodex are forgiving of occasional lapses.

Longer gaps

• Missed a week: restart at usual dose without special action
• Missed 2-4 weeks: restart at usual dose but call the treating team at the next opportunity
• Stopped for months: call before restarting - the treating team may want a review and updated bloods before resumption
• If on CAB, the LHRH agonist injection schedule is separate - missing an injection matters more than missing Casodex tablets

When missed doses become a pattern

Isolated missed doses are fine. A recurring pattern over weeks or months does affect outcomes. If missed doses become habitual, it usually reflects one of:

• Side effects that make the drug feel intolerable - discuss with treating team
• Cost issues - generic bicalutamide is cheap; discuss options
• Ambivalence about continuing - honest conversation is better than silent dropout
• Life pressures - simplify the reminder system

What changes with age

• Baseline bone density lower - fracture risk climbs faster on CAB
• Muscle mass lower - loss on CAB affects daily function sooner
• Falls risk higher - fractures more consequential
• Cardiovascular comorbidity common - metabolic effects of CAB more likely to matter clinically
• Polypharmacy interactions rise
• Cognitive reserve lower - fatigue and mood effects stack with age-related change
• Life expectancy calculation matters for whether long-term therapy fits the individual

Frailty over age

Age alone is a poor guide to what men will tolerate. A fit, active 78-year-old with newly diagnosed metastatic disease can do very well on CAB. A frail 68-year-old with multiple comorbidities may struggle disproportionately. Geriatric assessment tools such as G8, VES-13, or comprehensive geriatric assessment are used in many centres to guide decisions rather than birthdate alone.

Practical adjustments

• Same 50 mg or 150 mg dose - no age-based reduction
• Earlier bone protection - lower threshold to add bisphosphonate or denosumab on CAB
• Attention to falls - physiotherapy for balance work when energy drops
• Simplify medication regimens where possible
• Regular medication reviews - deprescribe unnecessary drugs to reduce interaction load
• Watch for cognitive change - do not attribute all fog to age; consider depression, sleep loss, medication side effects
• Consider monotherapy at 150 mg where disease allows - avoids most CAB-related problems in older men

Casodex versus newer agents in older men

Enzalutamide carries increased falls, seizure risk, and cognitive effects in older men. Apalutamide has similar concerns. Bicalutamide often tolerates better in this population despite modestly less anti-cancer effect. Where the newer drugs are affordable and available, the choice between Casodex-based CAB and a newer agent in an older man often comes down to a tolerability judgment - the treating team weighs individual factors carefully.

Common sick days

• Cold, flu, mild viral illness: continue Casodex if you can keep tablets down
• Stomach bug with vomiting: if you cannot keep tablets down for more than 24 hours, temporary hold is reasonable; the 6-day half-life means brief interruption has minimal clinical effect
• Fever without fluid loss: continue normally
• COVID-19 or similar systemic viral illness: continue Casodex; the drug does not affect infection outcome

Hospital admissions

• Tell the admitting team you are on Casodex - it can be missed on a busy admission
• The drug is usually continued through hospital stays
• If unable to swallow, bicalutamide can be paused for a few days without meaningful clinical effect
• Any new antibiotic or antifungal starting - check for QT and CYP3A4 interactions (Section 22, 23)
• Immobilisation during admission - matters if bone density is already low; discuss

Chemotherapy on top of Casodex

In advanced disease, docetaxel or cabazitaxel may be added to hormonal therapy. Casodex is typically continued alongside chemotherapy, though the treating team may adjust based on liver function and general tolerability. This is a specialist decision made with the medical oncology team.

When to hold Casodex temporarily

• Acute drug-induced liver injury (jaundice, dark urine, LFTs rising sharply)
• Severe skin reaction
• Severe interstitial lung symptoms
• Severe QT-related symptoms with cardiac assessment pending
• Severe fluid loss preventing oral intake for over 24-48 hours
• Under treating team guidance around major surgery or critical illness

The evidence base in prostate cancer

• Meta-analyses show reduced prostate cancer mortality in men who exercise regularly after diagnosis
• Randomised trials confirm reductions in ADT-related fatigue and improved quality of life
• Exercise preserves muscle mass and bone density on CAB
• Reduces long-term cardiovascular event risk
• Improves mood, cognitive function, and sleep quality
• Counteracts the muscle-to-fat body composition drift that CAB drives

What to aim for

ACS and ASCO exercise guidelines for cancer survivors recommend:

• 150 minutes weekly of moderate aerobic exercise - walking, swimming, cycling
• OR 75 minutes weekly of vigorous aerobic exercise
• Plus resistance training 2-3 times weekly - critical for preserving muscle mass on CAB
• Flexibility and balance work - important for older men at fall risk
• Any activity is better than none; scale up gradually

Resistance training specifics

For men on CAB, resistance training matters more than for the general population because of the muscle mass drift:

• Compound movements - squats, deadlifts, presses, rows
• Weights heavy enough that the last few reps feel challenging
• Progressive - increase gradually over weeks and months
• Adequate protein intake (1.0-1.2 g/kg body weight daily)
• Avoid overtraining - fatigue on CAB makes recovery matter more
• Supervised sessions initially if new to weights

Bone metastases and exercise

Men with bone metastases can and should exercise, but with modification. Physiotherapy-guided programmes reduce fracture risk and preserve function even in advanced disease. High-impact activities and heavy loading of affected bones are usually avoided; walking, cycling, swimming, and modified resistance training all remain valuable. Discuss with the treating team - a physiotherapist familiar with cancer bone disease can design a safe programme.

Stop exercise and get review if

• New chest pain or unusual shortness of breath
• Fainting or near-fainting
• Palpitations or irregular rhythm
• Sudden severe bone pain during activity - possible pathological fracture
• New leg weakness, dragging, or sensory change - urgent, possible spinal cord compression

The LHRH agonist options

• Leuprolide (Lupron, Prostap, Eligard) - monthly or 3-monthly injection; most widely used
• Goserelin (Zoladex) - monthly or 3-monthly subcutaneous implant
• Triptorelin (Decapeptyl) - monthly, 3-monthly, or 6-monthly injection
• Histrelin (Vantas) - yearly implant

How the combination works together

• LHRH agonist drops testosterone to castrate level over 3-4 weeks
• Casodex blocks residual androgen signalling from adrenal androgens and intracellular DHT
• Casodex also covers the transient testosterone rise (flare) from LHRH agonist start
• Combined effect approaches complete androgen blockade
• Meta-analysis shows modest survival benefit versus LHRH alone

Practical rhythm of CAB

Once established, therapy has two components on different schedules:

• Daily Casodex tablet - once every day at a consistent time
• Monthly or three-monthly clinic visit for LHRH injection - book ahead, do not miss
• Regular blood tests - PSA every 3-6 months, testosterone occasionally to confirm castrate levels, LFTs per Casodex monitoring, calcium and phosphate if on bone-modifying agents
• Bone density (DXA) every 1-2 years
• Yearly cardiovascular review

The LHRH antagonist alternative

LHRH antagonists (degarelix injection, relugolix oral tablet) do not cause a flare because they block the pituitary receptor directly rather than initially overstimulating it. Some men are treated with an LHRH antagonist plus Casodex, or with an LHRH antagonist alone. Relugolix is particularly interesting because it is oral (no injection needed) and has shown less cardiovascular event signal in the HERO trial. Where these newer options are available and affordable, some men and their teams prefer them.

When to consider stopping Casodex within CAB

After the initial flare cover period and stabilisation, the Casodex component can sometimes be stopped while the LHRH agonist continues. This "monotherapy with LHRH" works nearly as well as full CAB with fewer side effects. The decision depends on disease characteristics and treating team preference. Do not stop Casodex on your own - the decision is not automatic and needs discussion.

What the procedure involves

• Single fraction of external beam radiotherapy, typically 12-15 Gy
• Given to each breast in an outpatient session of 15-30 minutes
• Done before starting Casodex or within the first 2-4 weeks - earlier gives better protection
• Localised to breast tissue with minimal deep dose
• No hospital admission required

The evidence

• Randomised trials show 50-60 percent reduction in gynecomastia rates
• Reduction in breast tenderness slightly less pronounced
• Better outcomes when done before starting bicalutamide than after
• Much less effective when delayed until gynecomastia has developed

Side effects of the radiotherapy itself

• Mild skin redness at the treatment site
• Transient breast discomfort
• Very small theoretical long-term risk of radiation-induced breast cancer - real but tiny at these doses
• Slight change in skin pigmentation possible

Who should consider this

Men starting Casodex 150 mg monotherapy should be offered this option. Some centres offer it routinely; others discuss it only when the patient raises breast concerns. Ask about it if you have not been offered it - especially if body image or clothing considerations matter to you. Prophylactic tamoxifen 10-20 mg daily is an alternative or additional option (Section 15).

Not indicated for men on CAB at 50 mg

Gynecomastia rates on 50 mg CAB (about 30 percent) are much lower than on 150 mg monotherapy (70 percent). The balance of benefit versus radiotherapy risk is less clearly favourable at the lower dose. Prophylactic tamoxifen is more commonly used at 50 mg if breast issues emerge.

Typical durations by indication

When Casodex stops working

Bicalutamide-resistant progression is signalled by:

• Rising PSA on therapy despite castrate testosterone
• New symptomatic disease (bone pain, urinary symptoms)
• New metastases on imaging
• Progressive lymphadenopathy on scans

At this point disease has become castration-resistant prostate cancer (CRPC) if testosterone is confirmed at castrate levels. Treatment moves to second-line therapies - Section 31.

The antiandrogen withdrawal response

In roughly 20 percent of men, stopping bicalutamide when PSA is rising produces a paradoxical PSA fall for weeks to months. This "antiandrogen withdrawal response" reflects receptor mutations that make bicalutamide act as an agonist rather than an antagonist. Historically this was tried before switching to second-line therapy. Modern practice often skips this step and moves directly to enzalutamide, abiraterone, or another next-line agent based on trial evidence.

Stopping mechanics

Casodex does not need tapering. Stopping is a simple cessation. Blood levels fall over 2-3 weeks. Testosterone signalling recovers over the same period. Side effects fade over weeks to a few months - gynecomastia often only partly reverses, especially if it was well established. There is no rebound cancer effect from stopping - the tumour does not accelerate faster than its natural trajectory.

Second-generation androgen receptor inhibitors

mHSPC = metastatic hormone-sensitive; nmCRPC = non-metastatic castration-resistant; mCRPC = metastatic castration-resistant.

When to switch from Casodex to a newer agent

• Progression on Casodex-based CAB - PSA rising despite castrate testosterone
• New metastases on imaging
• Symptomatic progression
• High-risk newly diagnosed metastatic disease where newer agents give better first-line outcomes
• Non-metastatic castration-resistant disease where enzalutamide, apalutamide, and darolutamide have direct trial evidence

Trade-offs of the newer agents

Advantages:

• Better anti-cancer effect in most settings
• Much less gynecomastia
• Effective when bicalutamide has failed

Trade-offs:

• More expensive - meaningful for out-of-pocket costs
• Enzalutamide and apalutamide - increased falls, seizure risk, cognitive change (less with darolutamide)
• Abiraterone - needs concurrent low-dose prednisone; blood pressure, potassium, LFT monitoring
• Different rash profiles (apalutamide worst)
• Availability varies by country and insurance

The switching conversation

Whether to start with Casodex-based CAB and switch later, or start with a newer agent upfront, is a common question. In high-volume metastatic hormone-sensitive disease the evidence increasingly favours upfront enzalutamide, apalutamide, or abiraterone over classical CAB. In low-volume or asymptomatic disease, or in older frailer men, Casodex-based CAB remains a reasonable option. This is a treating team decision informed by individual factors including local availability and cost.

Absolute contraindications

• Known hypersensitivity to bicalutamide or excipients
• Women and children - not indicated
• Severe hepatic impairment at baseline
• Prior drug-induced hepatitis from bicalutamide - no rechallenge
• Concurrent terfenadine, astemizole, or cisapride (rarely encountered but firm interaction)

Relative contraindications - use with care

• Moderate hepatic impairment
• Congenital long QT syndrome or family history of sudden cardiac death
• Concurrent strong QT-prolonging drugs where combination cannot be avoided
• Bradycardia or heart block
• Severe uncontrolled cardiovascular disease
• Localised low-risk prostate cancer at 150 mg monotherapy dose (harmful per EPC data)
• Warfarin therapy without frequent INR monitoring

Reasons to stop Casodex

• Drug-induced liver injury of any severity
• Severe skin reaction
• Interstitial lung disease
• Symptomatic QT prolongation
• Disease progression despite therapy - switch to next-line agent
• Intolerable side effects despite management
• Completion of planned course (flare cover, defined-duration adjuvant)
• Change to newer androgen receptor inhibitor based on updated evidence or trial participation

Stopping mechanics

Casodex does not need tapering. The long half-life means the drug clears over 2-3 weeks after the last dose. Testosterone signalling recovers over the same period. Side effects fade over weeks to a few months. There is no rebound cancer risk from stopping - the concern is losing ongoing anti-cancer effect, not any drug withdrawal danger. Where continued androgen blockade is needed, the switch to another agent is planned before stopping bicalutamide rather than stopping first.

Storage

• Room temperature under 30 C, in original packaging
• Not in the bathroom - humidity degrades tablets
• Not in a hot car
• Out of reach of children and pets - bicalutamide in a small child would be dangerous
• Do not use past expiry date
• Return unused tablets to a pharmacy - do not flush or bin

Travel

• Pack Casodex in hand luggage, not checked baggage
• Take 30 percent more than you strictly need for the trip
• Original packaging with pharmacy label for customs
• Bring a letter from the treating team if travelling with a long supply
• Time zone changes - shift the dose gradually over a few days if the change is over 4 hours
• Coordinate LHRH injection schedule with travel dates - do not miss injections
• Travel insurance - declare prostate cancer and current therapy

Surgery on Casodex

• Tell every surgeon and anaesthetist about Casodex
• Major surgery - Casodex is usually continued, though the treating team may pause briefly around big procedures
• Minor surgery and dental work - continue normally
• Warfarin combined with Casodex - INR management around surgery needs careful coordination
• Anaesthetists should know about QT concerns if there is cardiac history

Yearly review checklist

A yearly Casodex review typically covers:

• PSA trend - the main disease marker
• Symptom review - hot flushes, gynecomastia, sexual function, fatigue, mood
• Adherence check - honest conversation about missed doses
• Full LFTs
• Full blood count
• Kidney function, calcium, phosphate
• Lipids, HbA1c or fasting glucose
• BP and cardiovascular risk assessment
• Bone density (DXA) every 1-2 years if on CAB
• Testosterone if uncertain about castrate status
• Imaging as clinically indicated
• Any new medications and interaction check
• Whether to continue, switch, or extend therapy
• Life issues - work, exercise, mental health, relationships

A closing thought

Casodex is an old, familiar, and thoroughly studied drug across many prostate cancer settings. It sits within an expanded therapy landscape that now includes enzalutamide, apalutamide, darolutamide, abiraterone, and other targeted agents. For many men - especially where cost, tolerability, or specific clinical context matter - bicalutamide remains a solid, dependable choice. Approaching it as a partnership over years rather than a passive prescription, taking side effects seriously enough to raise them with the treating team, and staying active and engaged with general health, are the elements that make long-term therapy work.